These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27422720)

  • 1. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
    Yoh K; Doi T; Ohmatsu H; Kojima T; Takahashi H; Zenke Y; Wacheck V; Enatsu S; Nakamura T; Turner K; Uenaka K
    Invest New Drugs; 2016 Oct; 34(5):584-95. PubMed ID: 27422720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
    Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
    Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
    [No Abstract]   [Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
    Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
    Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
    Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
    Zhu Y; Du Y; Liu H; Ma T; Shen Y; Pan Y
    Thorac Cancer; 2016 Nov; 7(6):663-669. PubMed ID: 27755796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
    Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
    Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
    Yang JC; Gadgeel SM; Sequist LV; Wu CL; Papadimitrakopoulou VA; Su WC; Fiore J; Saraf S; Raftopoulos H; Patnaik A
    J Thorac Oncol; 2019 Mar; 14(3):553-559. PubMed ID: 30529597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
    Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
    Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
    Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.